For the unversed, preclinical trials are conducted on animal models to evaluate the results, efficacy and safety of the vaccine candidate. If the results seem to be promising, then the vaccine is given the regulatory approval by the monitoring committee to go-ahead with Phase I of human trials. The vaccine being developed by Zydus Cadila was seen to successfully develop an immune system response in various animals including rabbits, rats, mice and guinea pigs. It was also observed that the vaccine candidate ZyCoV-D was tolerated well in the preclinical trials.
The company had taken two different approaches to develop the vaccine candidate. The first one being the development of a DNA vaccine by using the viral protein of the virus, which would, in turn, trigger the body’s immune system against the coronavirus. The other approach included producing the vaccine candidate using live attenuated recombinant measles virus.